Essilor, HPO enter exclusive global license agreement

Article

Charenton le Pont, France-Essilor has signed an exclusive and global license agreement with High Performance Optics (HPO), that complements its existing patent and technologies portfolio. This license agreement will allow Essilor to continue to focus on products with correction and preventive benefits and to roll out its portfolio of products around the world.

The pact enables Essilor to strengthen its mission of reaching the 4.2 billion people worldwide who need vision correction.

As a result of the company’s R&D and innovation processes, Essilor currently has approximately 5,600 patents throughout the world that help extend its strategy.

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Dr Luke Lindsell discusses retinal therapy and geographic atrophy at Controversies in Modern Eye Care 2025
Neda Shamie, MD, speaks on cataract and refractive surgery at CIME 2025.
Dr Selina McGee shares thoughts on pharmacological presbyopia correction at Controversies in Modern Eye Care 2025
Paul Hammond, OD, FAAO, presents a poster at ARVO 2025 on the creation of a conversion factor between 2 OCT devices to monitor glaucoma progression
What to know about legislative moves that have been made through May this year.
CIME 25: Dilsher Dhoot, MD, FASRS, is excited about emerging retinal therapies.
Robert Maloney, MD, MA, at the 2025 Controversies in Modern Eye Care meeting
Dr Jacob Lang at the 2025 Controversies in Modern Eye Care meeting
Steven Ferrucci, OD, FAAO, at Controversies in Modern Eyecare 2025
© 2025 MJH Life Sciences

All rights reserved.